Very few treatment options are available to patients with advanced pancreatic neuroendocrine tumors (NETs), but researchers at the Yale Cancer Center and Yale New Haven Health's Smilow Cancer Hospital found that patients treated with a combination of capecitabine and temozolomide had longer progression-free survival rates than those treated with temozolomide alone.
Drug manufacturer Hutchmed said the FDA sent the company a complete response letter indicating that the agency requires a multiregional clinical trial before approving the drug in the US.